Onco Wiki / Maladie

Leucémie myéloïde aiguë (non-APL)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-AML
TypeMaladie
Alias
AMLANLLLeucémie aiguë myéloïdeLeucémie aiguë non lymphocytaireГострий мієлобластний лейкозГострий мієлоїдний лейкоз (не-APL)
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ELN-AML-2022 SRC-ESMO-AML-2020 SRC-NCCN-AML-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9861/3
icd_o_3_topography["C42.1"]
icd_10C92.0
who_classificationAcute myeloid leukemia (per WHO 5th ed. / ICC 2022) — non-APL subtypes

Capacités

Notes

Risk-stratified archetype. The fundamental treatment split is fit-vs-unfit for intensive 7+3 induction (age, comorbidity, ECOG). Within fit patients, FLT3-ITD/TKD adds midostaurin (RATIFY); within unfit, ven+aza (VIALE-A) is now the 1L standard. APL (PML-RARA) is a separate disease with completely different therapy (ATRA + ATO) — see DIS-APL. STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme) — first myeloid disease end-to-end.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources